Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:ANIPNASDAQ:APGENASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$4.72-11.1%$4.34$1.58▼$7.27$420.75M-0.61.22 million shs1.02 million shsANIPANI Pharmaceuticals$58.32+0.9%$66.23$52.50▼$77.00$1.26B0.56303,166 shs364,442 shsAPGEApogee Therapeutics$36.88-6.6%$36.65$26.20▼$63.50$1.70B1.7525,065 shs624,707 shsIMCRImmunocore$32.04+2.8%$29.06$23.15▼$49.05$1.60B0.75390,271 shs787,427 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%-0.93%-0.93%+73.53%+206.94%ANIPANI Pharmaceuticals0.00%-3.94%-17.23%+6.02%-5.76%APGEApogee Therapeutics0.00%-1.08%+7.14%+19.42%-17.80%IMCRImmunocore0.00%+0.52%+3.32%+6.68%-32.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.4554 of 5 stars3.62.00.00.03.34.21.3ANIPANI Pharmaceuticals4.7877 of 5 stars4.53.00.03.33.23.31.3APGEApogee Therapeutics2.1332 of 5 stars3.50.00.00.03.04.20.0IMCRImmunocore2.9286 of 5 stars4.30.00.00.03.64.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.13Buy$9.83108.33% UpsideANIPANI Pharmaceuticals 3.00Buy$80.1337.39% UpsideAPGEApogee Therapeutics 3.00Buy$94.60156.51% UpsideIMCRImmunocore 2.55Moderate Buy$58.8983.80% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ANIP, APGE, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/9/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/7/2025AMLXAmylyx PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.005/6/2025AMLXAmylyx PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals-$1.27M-330.77$0.86 per share5.51$6.42 per share0.74ANIPANI Pharmaceuticals$674.07M1.87$6.46 per share9.03$21.13 per share2.76APGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/AIMCRImmunocore$333.58M4.81N/AN/A$7.42 per share4.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/14/2025 (Estimated)ANIPANI Pharmaceuticals$18.78M-$1.27N/A13.85N/A-1.28%15.87%6.88%8/5/2025 (Estimated)APGEApogee Therapeutics-$83.99M-$3.60N/AN/AN/AN/A-21.81%-20.94%8/11/2025 (Estimated)IMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/14/2025 (Estimated)Latest AMLX, ANIP, APGE, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) million3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.0221.53%N/AN/A N/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A4.554.55ANIPANI Pharmaceuticals1.522.741.97APGEApogee TherapeuticsN/A16.3916.39IMCRImmunocore1.033.783.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%ANIPANI Pharmaceuticals76.05%APGEApogee Therapeutics79.04%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%ANIPANI Pharmaceuticals11.10%APGEApogee Therapeutics42.77%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million60.53 millionOptionableANIPANI Pharmaceuticals60021.66 million18.36 millionOptionableAPGEApogee Therapeutics9146.05 million28.77 millionOptionableIMCRImmunocore32050.07 million45.48 millionOptionableAMLX, ANIP, APGE, and IMCR HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Decreases Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 26 at 4:25 AM | marketbeat.comWoodline Partners LP Has $9.68 Million Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)May 25 at 4:41 AM | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Position Trimmed by Two Sigma Advisers LPMay 24 at 4:52 AM | marketbeat.comMillennium Management LLC Cuts Stake in Immunocore Holdings plc (NASDAQ:IMCR)May 24 at 3:57 AM | marketbeat.comIs it a Good Idea to Invest in Immunocore Stock Right Now?May 23, 2025 | zacks.comTema Etfs LLC Makes New Investment in Immunocore Holdings plc (NASDAQ:IMCR)May 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Shares in Immunocore Holdings plc (NASDAQ:IMCR)May 21, 2025 | marketbeat.comTang Capital Management LLC Has $45.89 Million Position in Immunocore Holdings plc (NASDAQ:IMCR)May 20, 2025 | marketbeat.comPolar Capital Holdings Plc Sells 387,732 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 18, 2025 | marketbeat.comWall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?May 16, 2025 | zacks.comBNP Paribas Financial Markets Makes New Investment in Immunocore Holdings plc (NASDAQ:IMCR)May 16, 2025 | marketbeat.comJefferies Financial Group Inc. Makes New $4.87 Million Investment in Immunocore Holdings plc (NASDAQ:IMCR)May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)May 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes $3.15 Million Position in Immunocore Holdings plc (NASDAQ:IMCR)May 13, 2025 | marketbeat.comImmunocore FY2025 EPS Estimate Boosted by Cantor FitzgeraldMay 13, 2025 | marketbeat.comQ2 EPS Estimates for Immunocore Boosted by Leerink PartnrsMay 13, 2025 | marketbeat.comCrestline Management LP Buys New Position in Immunocore Holdings plc (NASDAQ:IMCR)May 12, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of "Moderate Buy" by AnalystsMay 12, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Stock Position Lifted by Barclays PLCMay 10, 2025 | marketbeat.comDeep Track Capital LP Invests $15.32 Million in Immunocore Holdings plc (NASDAQ:IMCR)May 9, 2025 | marketbeat.comAquatic Capital Management LLC Sells 9,500 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMLX, ANIP, APGE, and IMCR Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$4.72 -0.59 (-11.11%) Closing price 04:00 PM EasternExtended Trading$4.78 +0.07 (+1.38%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.ANI Pharmaceuticals NASDAQ:ANIP$58.32 +0.53 (+0.92%) Closing price 04:00 PM EasternExtended Trading$58.31 -0.01 (-0.02%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Apogee Therapeutics NASDAQ:APGE$36.88 -2.60 (-6.59%) Closing price 04:00 PM EasternExtended Trading$36.88 0.00 (0.00%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Immunocore NASDAQ:IMCR$32.04 +0.88 (+2.82%) Closing price 04:00 PM EasternExtended Trading$32.12 +0.08 (+0.23%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
